Eylem Emel Arıkan

Eylem Emel Arıkan

Auto-generated profile, based on publicly available information

Eylem Emel Arıkan

Department of Dermatology and Venereology, Fatih Sultan Mehmet Training and Research Hospital, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Anais Brasileiros de Dermatologia
Verified
Journal Article
Open access
ITIlteris Oguz Topal
Ilteris Oguz Topal
SBSevim Baysak
Sevim Baysak
IAİlKnur Kıvanç Altunay
İlKnur Kıvanç Altunay
APAsude Kara Polat
Asude Kara Polat
EAEylem Emel Arıkan
Eylem Emel Arıkan
AKAyşe Serap Karadağ
Ayşe Serap Karadağ
Clinical studies have demonstrated that IL-17A inhibition with secukinumab is effective for clearing the skin of patients with psoriasis and has a favorable safety profile. The authors aim to determine whether secukinumab is effective and safe for the treatment of moderate-to-severe chronic psoriasis based on clinical experience with this drug. The authors conducted a multicenter retrospective study in nine referral centers and included patients with psoriasis who had received secukinumab between March 2018 to November 2020. Data on demographic characteristics, Psoriasis Area and Severity Index (PASI) scores, and previous treatments were collected from medical records. Patients were evaluated at 12, 24, and 52 weeks with respect to response to treatment and side effects. In total, 229 patients were recruited for the study. A PASI score improvement of ≥90 points over the baseline was achieved by 79%, 69.8%, and 49.3% of patients at weeks 12, 24, and 52, respectively. The most common adverse events wereCandida infections and fatigue. In total, 74 (32%) patients discontinued treatment by week 52, including due to adverse events, or secondary ineffectiveness. Retrospective design. These findings suggest that secukinumab therapy is reasonably effective in patients with moderate-to-severe psoriasis. Comorbidities and time length of the disease can affect the response to treatment. The rates of adverse events were high in this patient population.

1 June 2020 in Dermatoz
Verified
Journal Article
Closed access
AKAyşe Serap Karadağ
Ayşe Serap Karadağ
TUTugba Kevser Uzuncakmak
Tugba Kevser Uzuncakmak
EZEbru Itır Zemheri
Ebru Itır Zemheri
EAEylem Emel Arıkan
Eylem Emel Arıkan
ŞÖŞeyma Özkanlı
Şeyma Özkanlı
NANecmettin Akdeniz
Necmettin Akdeniz

1 September 2022 in Anais Brasileiros de Dermatologia (Versão em Português)
Verified
Journal Article
Open access
ITIlteris Oguz Topal
Ilteris Oguz Topal
SBSevim Baysak
Sevim Baysak
IAİlknur Kıvanç Altunay
İlknur Kıvanç Altunay
APAsude Kara Polat
Asude Kara Polat
EAEylem Emel Arıkan
Eylem Emel Arıkan
AKAyşe Serap Karadağ
Ayşe Serap Karadağ